Filing Flows › International Stem Cell (ISCO) › Q2 2026 › vs Q1 2026
International Stem Cell (ISCO) Q2 2026 vs Q1 2026 (quarter over quarter)
International Stem Cell's revenue rose $360K (+16%) from $2.3M in Q1 2026 to $2.7M in Q2 2026. The biggest changes: Biomedical Market +$354K (+16%); Anti Aging Skincare Market +$6K (+4%).
International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%, net loss $71K, operating cash flow $167K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.0% | 4.2% | +1.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Biomedical Market | $2.5M | $2.2M | $354K | +16% |
| Anti Aging Skincare Market | $151K | $145K | $6K | +4% |
| Revenue | $2.7M | $2.3M | $360K | +16% |
| Net loss | $71K | $220K | −$149K | -68% |
| Costs & expenses | $2.7M | $2.5M | $211K | +8% |
| Operating costs | $2.7M | $2.5M | $205K | +8% |
| Interest & other, net | $36K | $30K | $6K | +20% |
| Cost of revenue | $1.2M | $954K | $263K | +28% |
| Research & development | $155K | $156K | −$1K | -0.6% |
| Sales & marketing | $276K | $273K | $3K | +1% |
| General & admin | $1.1M | $1.1M | −$60K | -5% |
| Operating cash sources | $238K | $341K | −$103K | -30% |
| Depreciation & amortization | $28K | $34K | −$6K | -18% |
| Share-based compensation | $59K | $64K | −$5K | -8% |
| Working capital & other | $151K | $243K | −$92K | -38% |
| Net loss absorbed | $71K | $220K | −$149K | -68% |
| Operating cash flow | $167K | $121K | $46K | +38% |
| Free cash flow (OCF − capex) | $160K | $98K | $62K | +63% |
| Capital expenditures | $7K | $23K | −$16K | -70% |
Questions
How much did International Stem Cell's revenue grow quarter over quarter in Q2 2026?
International Stem Cell's revenue rose $360K (+16%) from $2.3M in Q1 2026 to $2.7M in Q2 2026.
What drove International Stem Cell's revenue change in Q2 2026?
Biomedical Market +$354K (+16%); Anti Aging Skincare Market +$6K (+4%).